Go here to read the rest:
First patient dosed in second Phase 2 add-on Ketamine Trial in Treatment-Resistant Depression (TRD)

Continued here:
Allogene Therapeutics Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to ALLO-501A for Large B Cell Lymphoma

Read the rest here:
SCYNEXIS Announces Submission of Supplemental New Drug Application of BREXAFEMME® (ibrexafungerp tablets) to the U.S. Food and Drug Administration...

Go here to read the rest:
CorMedix to Participate at the JMP Securities Life Sciences Conference

See the original post here:
Healthy Extracts New Clinical Study Highlights UBN RELIEF Naturally Alleviates Migraine Symptoms

Originally posted here:
Albireo to Present New Data at the EASL International Liver Congress™ 2022

See the rest here:
Vaxart Announces Adjournment of Annual Meeting of Stockholders

Go here to see the original:
Genmab to Participate in a Fireside Chat at the Goldman Sachs 43rd Annual Global Healthcare Conference

See the article here:
Cerevance to Participate in Panel Discussion During the 2022 BIO International Convention

Go here to see the original:
MacroGenics to Participate in Upcoming Investor Conference

Original post:
Iovance Biotherapeutics to Present at Upcoming Conferences

See more here:
HilleVax Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress

Here is the original post:
Opiant Pharmaceuticals and Aptar Pharma Expand Long-Term Collaboration for the Manufacture of Unidose Nasal Spray for OPNT003, Nasal Nalmefene

Go here to see the original:
Tonix Pharmaceuticals Announces Presentation of Licensed Antiviral Drug Technology at the 4th Symposium of the Canadian Society for Virology

Read more here:
Terns Pharmaceuticals to Present Clinical Data on Multiple NASH Programs at the EASL International Liver Congress 2022

Read the rest here:
Celularity To Be Added To The Russell 3000® Index And The Small-Cap Russell 2000®

View post:
Correction: Orphazyme Announces Publication of 2021 Financial Results and Annual Report

Continue reading here:
Santhera and ReveraGen to Present New Data with Vamorolone at 2022 Parent Project Muscular Dystrophy Conference

Visit link:
European Commission approves Roche’s Tecentriq as adjuvant treatment for a subset of people with early-stage non-small cell lung cancer

Follow this link:
U.S. FDA approves Foundation Medicine’s FoundationOne®CDx as a companion diagnostic for Roche’s Rozlytrek® (entrectinib)